Abstract
Spinal muscular atrophy (SMA) is the most common genetically inherited neurodegenerative disease resulting in infant mortality. SMA is caused by genetic deletion or mutation in the survival of motor neuron 1 (SMN1) gene, which results in reduced levels of the survival of motor neuron (SMN) protein. SMN protein deficiency preferentially affects α- motor neurons, leading to their degeneration and subsequent atrophy of limb and trunk muscles, progressing to death in severe forms of the disease. More recent studies have shown that SMN protein depletion is detrimental to the functioning of other tissues including skeletal muscle, heart, autonomic and enteric nervous systems, metabolic/endocrine (e.g. pancreas), lymphatic, bone and reproductive system. In this review, we summarize studies discussing SMN protein’s function in various cell and tissue types and their involvement in the context of SMA disease etiology. Taken together, these studies indicate that SMA is a multi-organ disease, which suggests that truly effective disease intervention may require body-wide correction of SMN protein levels.
Keywords: Gene therapy, motor neuron, neuromuscular disease, spinal muscular atrophy, survival of motor neuron, therapeutics.
Current Molecular Medicine
Title:Spinal Muscular Atrophy: More than a Disease of Motor Neurons?
Volume: 16 Issue: 9
Author(s): L. A. Nash, J. K. Burns, J. Warman Chardon, R. Kothary and R. J. Parks
Affiliation:
Keywords: Gene therapy, motor neuron, neuromuscular disease, spinal muscular atrophy, survival of motor neuron, therapeutics.
Abstract: Spinal muscular atrophy (SMA) is the most common genetically inherited neurodegenerative disease resulting in infant mortality. SMA is caused by genetic deletion or mutation in the survival of motor neuron 1 (SMN1) gene, which results in reduced levels of the survival of motor neuron (SMN) protein. SMN protein deficiency preferentially affects α- motor neurons, leading to their degeneration and subsequent atrophy of limb and trunk muscles, progressing to death in severe forms of the disease. More recent studies have shown that SMN protein depletion is detrimental to the functioning of other tissues including skeletal muscle, heart, autonomic and enteric nervous systems, metabolic/endocrine (e.g. pancreas), lymphatic, bone and reproductive system. In this review, we summarize studies discussing SMN protein’s function in various cell and tissue types and their involvement in the context of SMA disease etiology. Taken together, these studies indicate that SMA is a multi-organ disease, which suggests that truly effective disease intervention may require body-wide correction of SMN protein levels.
Export Options
About this article
Cite this article as:
Nash A. L., Burns K. J., Chardon Warman J., Kothary R. and Parks J. R., Spinal Muscular Atrophy: More than a Disease of Motor Neurons?, Current Molecular Medicine 2016; 16 (9) . https://dx.doi.org/10.2174/1566524016666161128113338
DOI https://dx.doi.org/10.2174/1566524016666161128113338 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Understanding Genetic Factors in Idiopathic Scoliosis, a Complex Disease of Childhood
Current Genomics Therapeutic Approaches to Polyglutamine Diseases: Combating Protein Misfolding and Aggregation
Current Pharmaceutical Design Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Recent Advances in Self-Assembled Fluorescent DNA Structures and Probes
Current Topics in Medicinal Chemistry Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson’s Disease Associated Mutations
Current Protein & Peptide Science Derivation of Motor Neurons from three Clonal Human Embryonic Stem Cell Lines
Current Neurovascular Research Transient Receptor Potential Vanilloid 1 and Xenobiotics
CNS & Neurological Disorders - Drug Targets Evaluation of the Radioprotective Effects of Melatonin Against Ionizing Radiation-Induced Muscle Tissue Injury
Current Radiopharmaceuticals MR-Based In Vivo Analysis of Joint Biomechanics and its Relevance in the Pathogenesis of Osteoarthritis
Current Rheumatology Reviews Editorial: Big Data and New Drug Discovery: Tackling “Big Data” for Virtual Screening of Large Compound Databases
Current Computer-Aided Drug Design Induced Pluripotent Stem Cells in Regenerative Medicine and Disease Modeling
Current Stem Cell Research & Therapy A Possible Approach for Stem Cell Gene Therapy of Fanconi Anemia
Current Gene Therapy Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases
Current Pharmaceutical Design REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets Inflammation in Neurodegenerative Disorders: Friend or Foe?
Current Aging Science Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews Magnetic Field-Assisted Gene Delivery: Achievements and Therapeutic Potential
Current Gene Therapy Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
Current Pharmaceutical Design